InMed Pharmaceuticals Announces Promising Results for Alzheimer's Drug Candidate
InMed Pharmaceuticals Announces Promising Results for Alzheimer's Drug Candidate
Key Takeaways (TLDR)
Investing in InMed Pharmaceuticals offers a competitive advantage in the biopharmaceutical industry.
The long-term study validates the effectiveness of INM-901 as a potential treatment for Alzheimer’s Disease.
The promising outcomes of the study bring hope for a better future in Alzheimer’s disease treatment.
InMed Pharmaceuticals' INM-901 shows potential for significant advancements in Alzheimer's Disease research.
Why it Matters
This news matters as it represents a significant step forward in the development of a potential treatment for Alzheimer’s Disease, a condition with high unmet medical needs.
Summary
InMed Pharmaceuticals (NASDAQ: INM) has announced promising outcomes from a long-term preclinical study of its Alzheimer’s Disease (“AD”) drug candidate, INM-901, confirming and expanding upon previous results.
This news story relied on a press release distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is InMed Pharmaceuticals Announces Promising Results for Alzheimer's Drug Candidate.